Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Orexo===Buprenorphine/naloxone
Entity

Orexo===Buprenorphine/naloxone

Tracked across 2 events · 15 articles · First seen Mar 06, 2026 · Last active Mar 06, 2026

Sentiment
0
Attention
2
Events
2
Relationships
1
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (2)
2 0
Business
Orexo Restructures Management, Appoints Lisa Moore
The divestment of Orexo===Buprenorphine/naloxone in the US market is a key reason for Orexo's organizational changes, allowing the company to refocus its efforts.
Mar 06, 2026 · 8 articles
2 0
Business
Orexo R&D Day on Strategy and AmorphOX
The divestment of Orexo===Buprenorphine/naloxone in the US is a key event that has led to Orexo's updated strategy and R&D priorities, which will be discussed at the R&D Day.
Mar 06, 2026 · 7 articles
Relationships (1)
Orexo divested product ↔ Orexo===Buprenorphine/naloxone Orexo===Buprenorphine/naloxone was a product of Orexo that has been divested in
NEWSDESK
Track Orexo===Buprenorphine/naloxone live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.